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ess: malcolm.campbellSummary Formoterol is a long-acting b2-agonist with a rapid onset of effect in
patients with chronic obstructive pulmonary disease (COPD), making it potentially
suitable for both maintenance and as-needed bronchodilator treatment.
To evaluate the efficacy and tolerability of maintenance formoterol in patients
with COPD and to compare the effects of additional formoterol as needed with
terbutaline.
In this 6-month, double-blind study, 657 patients with COPD (X40 years, forced
expiratory volume in 1 s [FEV1] 40–70% predicted normal) were randomized to
formoterol 9mg twice daily (bid) plus terbutaline 0.5mg as needed (FORM bid),
formoterol 9 mg bid plus formoterol 4.5 mg as needed (FORM bid+prn), or placebo bid
plus terbutaline 0.5mg as needed (placebo), all administered via Turbuhalers.
Primary efficacy variables were FEV1 and the sum of breathlessness and chest
tightness scores combined symptom score.
Formoterol significantly (Po0:01) increased FEV1 compared with placebo: FORM
bid 6.5% (95% CI: 2.5, 10.7%); FORM bid+prn 11.8% (95% CI: 7.7, 16.2%). Combined
symptom score decreased significantly in both formoterol groups compared with
placebo: FORM bid 0.27 (95% CI: 0.49, 0.06; P ¼ 0:012); FORM bid+prn 0.32
(95% CI: 0.53, 0.11; P ¼ 0:0026). Similar significant (Po0:05) improvements wereElsevier Ltd. All rights reserved.
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M. Campbell et al.1512seen in both formoterol groups for morning peak expiratory flow, cough and sleep
scores, and reliever use.
In this study, formoterol 9mg bid via Turbuhalers as maintenance therapy, with
either formoterol or terbutaline as rescue medication, provided sustained improve-
ments in lung function and COPD symptoms. Both formoterol regimens were well
tolerated with no differences in adverse events or electrocardiogram profiles.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Inhaled bronchodilators (anticholinergics and b2-
agonists) are central to the symptomatic manage-
ment of chronic obstructive pulmonary disease
(COPD). The overall goals of maintenance bronch-
odilator treatment are to induce bronchodilation,
facilitate expectoration and reduce symptoms, as
well as enhancing health status.1,2 Long-acting b2-
agonists, such as formoterol and salmeterol, have a
duration of action of at least 12 h3,4 and are
suitable for regular maintenance therapy in pa-
tients with COPD.1
Maintenance formoterol therapy was evaluated
in a 3-month, placebo-controlled study, performed
in 692 patients with COPD showing poorly reversible
bronchoconstriction. The study showed that for-
moterol 9 and 18 mg twice-daily (bid) via Turbuha-
lers were well tolerated, improved lung function
and reduced daily symptoms of breathlessness.5
Other clinical studies in COPD have also shown that
regular maintenance treatment with long-acting
b2-agonists enhance health status as effectively if
not better than as-needed short-acting b2-agonists,
anticholinergics, or placebo.6–9 An additional ben-
efit of long-acting b2-agonists is a reduction in the
need for relief medication to control breakthrough
symptoms, although relief medication is still
normally required on a daily basis.4,5 Formoterol
is a unique b2-agonist with both a rapid onset of
effect, similar to salbutamol,10,11 and a long
duration of action, similar to salmeterol.12 For-
moterol may therefore be suitable for both main-
tenance and as-needed treatment in COPD.
The primary objective of this 6-month study was
to provide additional evidence for the long-term
efficacy and safety of formoterol 9 mg bid via
Turbuhalers. Previous studies have examined for-
moterol in COPD for only 3 months.5,6,9 A novel
feature of the study design was the inclusion of a 3-
week placebo washout period; this permitted
detection of any loss of efficacy or rebound
increases in symptoms after withdrawal of formo-
terol, to further validate the study findings. As
patients were required to use separate reliever
medication, a secondary objective of the study wasto evaluate the safety and efficacy of using
additional, as-needed formoterol compared with
terbutaline as needed.Methods
A randomized, double-blind, placebo-controlled,
parallel-group study conducted in 73 centers in
eight countries (Bulgaria, Hungary, Israel, The
Netherlands, Romania, Spain, Sweden, and the
UK).Patients
Patients X40 years of age with a clinical diagnosis
of COPD were eligible if they met the inclusion
criteria: symptoms X2 years; pre-bronchodilator
forced expiratory volume in 1 s (FEV1) 40–70%
predicted normal13 and FEV1/slow vital capacity
(slow VC)o70%; current or previous smokers with a
history of smoking of X10 pack-years. Patients
were excluded from the study if they had disease
onset before 40 years of age with any history of
asthma or seasonal allergic rhinitis; had changed
their dose of inhaled corticosteroids, used either
oral steroids or had experienced a significant
exacerbation of COPD within the last month; had
any disorder that might, in the investigator’s
opinion, put them at risk (including significant or
unstable cardiovascular disorder); had a require-
ment for domiciliary oxygen; or were females of
child bearing potential.
All patients gave written informed consent and
the study was approved by an independent Ethical
Committee in all centers.Study design
At visit 1 (3 weeks), eligible patients entered a
3-week, open, run-in period during which they
received as-needed terbutaline 0.5mg for symptom
relief. Providing that their combined symptom
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least 10 days of the run-in period, patients were
randomized at visit 2 (time 0) to receive 6 months
of treatment with either: formoterol (Oxiss) 9 mg
bid plus as-needed terbutaline (Bricanyls) 0.5mg
(FORM bid); formoterol 9 mg bid plus as-needed
formoterol 4.5 mg (FORM bid+prn); or placebo plus
as-needed terbutaline 0.5mg (placebo), all via the
dry powder inhaler Turbuhalers. Treatment was
randomized in balanced blocks using a computer-
generated scheme provided in coded envelopes.
The double-blind treatment period was followed by
a 3-week, single-blind placebo washout, during
which all treatment groups received placebo bid
plus as-needed terbutaline, to evaluate the effect
of withdrawal of formoterol treatment.
Patients were allowed to use inhaled and nasal
corticosteroids, without modification of dosage or
frequency of administration, throughout the study.
Disodium cromoglycate, ephedrine, antihistamines,
beta-blockers, and bronchodilators other than
study medication were not allowed during the
study. No limit on the daily number of rescue
inhalations of formoterol or terbutaline was speci-
fied.
Reversibility to both formoterol 9 mg and terbuta-
line 0.5mg was assessed in a random crossover
design at visits 1 and 2, by measuring FEV1 pre- and
15min post-bronchodilator.Variables
The two primary efficacy variables were FEV1 and
CSS. Secondary variables included morning peak
expiratory flow (PEF), slow VC, symptoms of COPD
(including breathlessness, chest tightness, cough,
and sleep disturbance), as-needed medication use,
time to first severe exacerbation, and health-
related quality of life (HRQL).
FEV1 and slow VC were measured at clinic visits
and the highest value from three technically
satisfactory maneuvers was recorded. Patients took
their regular study drug at home 30min to 2 h
before the lung function tests and refrained from
using rescue medication for 6 h before lung function
tests. COPD symptoms (breathlessness, chest tight-
ness, cough, and sleep disturbance), morning PEF,
and both regular study and as-needed medication
use were recorded daily on electronic diary cards,
which dated and time-stamped all entries and
prevented retrospective data entry. Patients as-
sessed the intensity of individual COPD symptoms
on a scale of 0–4 per day (0 ¼ no symptoms,
4 ¼ severe symptoms). CSS was defined as thesum of breathlessness and chest tightness scores
thus the CSS score ranged from 0 to 8. Morning PEF
was measured with a MiniWrights peak flow meter
on waking, before taking the first dose of study
medication and preferably46 h after the last dose
of rescue medication.
HRQL was recorded using the St. George’s
Respiratory Questionnaire (SGRQ).14 This question-
naire assesses HRQL in three domains: Symptoms
(distress due to respiratory symptoms), Activity
(disturbance of physical activity), and Impacts
(overall impact on daily life and well-being).
Questionnaires were completed, before any other
study-related procedures, in the patient’s own
language during visits 2, 3 (2 months), 5 (6 months),
and 6 (end of washout period). Severe COPD
exacerbations, defined as the need for oral
steroids, change in dose of inhaled corticosteroids,
or need for antibiotics or hospitalization, were
recorded at the clinic visits.
Adverse events (AEs) were identified by means of
a standard question at each clinic visit and from
patient diary data. Standard clinical-chemical
measurements (including serum glucose and serum
potassium levels), blood pressure measurements
and electrocardiogram (ECG) assessments were
made at visits 1 and 5.Statistical analysis
An intention-to-treat approach was used through-
out. With 200 patients per treatment group,
assuming a standard deviation of 0.20 log units for
FEV1 and 1 point for CSS, there was a 90% chance of
detecting a true difference of 0.06 log units (i.e. a
relative difference of 6.0%) and 0.32 points for FEV1
and CSS, respectively, at the 5% significance level
using a two-sided test.
For spirometry variables, values at visits 2 and 6
constituted the run-in and follow-up period values,
respectively, and the average over visits 4 (4 months)
and 5—the treatment period value. Period means for
diary data were computed over the run-in period,
the last 90 days of the treatment period, and over
the follow-up period.
Most variables were compared between treat-
ments using an analysis of variance model with
treatment and country as factors, and baseline as a
covariate. When analyzing the treatment period,
the run-in values constituted baseline and when
analyzing the follow-up data, the treatment period
values constituted baseline. For SGRQ data, values
from each visit were analyzed separately. Time-to-
event variables were described using Kaplan–Meier
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the log-rank test (withdrawals) or a Cox propor-
tional hazards model (severe exacerbations).
For the two primary efficacy variables, subgroup
analyses were performed, stratifying patients by
use of inhaled corticosteroids (yes vs. no), smoking
habit (current vs. ex-smoker), and FEV1 reversi-
bility (below vs. above median reversibility ex-
pressed as % predicted normal) at visit 1.Results
The first patient entered the study in July 2000, the
last patient completed randomized treatment in
October 2001 and the last patient completed
follow-up in November 2001. Of the 906 patients
enrolled, 657 were randomized to treatment. Of
the 249 patients not randomized, 218 did not meet
eligibility criteria, 30 patients were withdrawn
because of AEs, and one patient was lost to
follow-up. Ninety-eight patients were withdrawnTable 1 Demographics and baseline characteristics at v
FORM bid
(n ¼ 215)
FORM bid+pr
(n ¼ 225)
Male (%) 61 71
Age, years (range) 60 (40–84) 60 (40–83)
FEV1, L (range) 1.45 (0.63–3.11) 1.51 (0.67–3
Slow VC, L (range) 2.70 (1.01–6.00) 2.81 (0.94–5
Smoking status, %
(current/former)
54/46 56/44
Smoking history,
pack-years (range)
37 (10–99) 38 (10–99)
FEV1, % predicted
normal (range)
53.0 (20.0–87.3) 54.4 (29.5–1
FEV1, % VC (range)
 54.4 (27.4–72.2) 54.7 (28.8–9
Reversibility, %
predicted normal
(range)
5.1 (–7.3–31.2) 4.6 (–9.1–62
ICS at enrollment (%) 47 45
Anticholinergics at
enrollment (%)
11 12
Xanthines at
enrollment (%)
11 13
Reliever, doses/day
(range)
3.2 (0.0–23.6) 2.7 (0.0–26.
CSS, 0–8 scale
(range)
3.3 (0.0–6.4) 3.1 (0.3–6.1
SGRQ score, 0–100
scale (range)
50.3 (8.3–90.6) 46.0 (2.0–97
FORM bid, formoterol bis in die (twice-daily); FORM bid+prn, form
forced expiratory volume in 1 s; VC, vital capacity; ICS, inhaled
George’s Respiratory Questionnaire.
Sixteen patients outside the inclusion/exclusion criteria wereduring randomized treatment (FORM bid: n ¼ 30;
FORM bid+prn: n ¼ 29; placebo: n ¼ 39), 31 pa-
tients were withdrawn due to AEs, three were lost
to follow-up, 23 due to eligibility criteria, and 41
due to other reasons. Two patients were withdrawn
during the follow-up period: one due to an AE
(FORM bid) and one because of other reasons (FORM
bid+prn). There was no statistically significant
difference in withdrawal rates between groups
during the treatment period (P ¼ 0:109).
Demographic and other patient characteristics
were generally well balanced across the treatment
groups (Table 1). Reversibility testing in 606
patients at visits 1 and 2 gave similar increases
from baseline in FEV1 with terbutaline (8.9%) and
formoterol (9.9%; P ¼ 0:133). The median reversi-
bility at visit 1 was 3.78% predicted normal.Lung function
FORM bid and FORM bid+prn significantly increased
FEV1 compared with placebo (Po0:01 andisit 1.
n Placebo
(n ¼ 217)
All
(n ¼ 657)
73 68
60 (40–82) 60 (40–84)
.59) 1.55 (0.65–3.86) 1.50 (0.63–3.86)
.29) 2.80 (0.83–5.34) 2.77 (0.83–6.00)
55/45 55/45
37 (10–99) 37 (10–99)
10.2) 54.1 (35.7–75.9) 53.9 (20.0–110.2)
7.4) 54.7 (35.2–80.7) 54.6 (27.4–97.4)
.5) 4.7 (–15.2–31.2) 4.8 (–15.2–62.5)
44 45
12 12
11 12
9) 2.9 (0.0–26.9) 2.9 (0.0–26.9)
) 3.1 (0.0–7.6) 3.2 (0.0–7.6)
.4) 46.7 (10.8–92.2) 47.7 (2.0–97.4)
oterol bis in die (twice-daily)+pro re nata (as-needed); FEV1,
corticosteroids; CSS, combined symptom score; SGRQ, St.
included in the data analysis.
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Figure 1 (a) Mean changes in forced expiratory volume in
1 s (FEV1) during the run-in and 6-month treatment
periods. Po0:01, Po0:001 vs. placebo; #Po0:05 vs.
FORM bid average of 4 and 6 months. FORM bid,
formoterol bis in die (twice-daily); FORM
bid+prn ¼ formoterol bis in die (twice-daily)+pro re nata
(as-needed); FEV1, forced expiratory volume in 1 s. (b)
Mean changes in morning peak expiratory flow (PEF)
during the run-in and 6-month treatment periods.
Po0:001 vs. placebo. FORM bid, formoterol bis in die
(twice-daily); FORM bid+prn, formoterol bis in die (twice-
daily)+pro re nata (as-needed); PEF, peak expiratory flow.
Maintenance and as-needed formoterol in COPD 1515Po0:001, respectively) (Table 2; Fig. 1a). FORM
bid+prn also improved FEV1 compared with FORM
bid (Po0:05) (Table 2; Fig. 1a). Expressed in liters,
FORM bid and FORM bid+prn improved FEV1 by
92mL (31–153), Po0:01 and 163mL (103–223),
Po0:001, respectively, compared with placebo;
FORM bid+prn also increased FEV1 by 71mL
(11–131), Po0:05 compared with FORM bid. These
improvements were seen irrespective of smoking
status or use of concomitant inhaled corticosteroids
(data not shown). In the lower reversibility group
ARTICLE IN PRESS
Figure 3 Reliever medication use during the randomized
treatment period. FORM bid+prn, formoterol bis in die
(twice-daily)+pro re nata (as-needed); FORM bid, for-
moterol bis in die (twice-daily).
M. Campbell et al.1516(o3.78% predicted) FEV1 increased by 5.9% (95% CI:
0.5, 11.6%; Po0:05) in the FORM bid group and by
14.7% (95% CI: 8.9, 20.7%; Po0:001) in the FORM
bid+prn group compared with placebo. In the
higher reversibility group (43.78% predicted)
FEV1 increased by 7.4% (95% CI: 1.6, 13.4%;
Po0:05) in the FORM bid group and by 8.2% (95%
CI: 2.4, 14.4%; Po0:01) in the FORM bid+prn group
compared with placebo.
Both formoterol groups increased pre-treatment
morning PEF and slow VC vs. placebo, but there
were no significant differences between the FORM
bid+prn and FORM bid groups (Table 2 and Fig. 1b).
Symptoms and reliever use
The mean decreases from baseline in CSS were
significantly greater for FORM bid (Po0:05) and
FORM bid+prn (Po0:01) than in the placebo group
(Table 2). There was no significant difference in CSS
between the formoterol treatment groups.
Furthermore, smoking status, use of concomitant
inhaled corticosteroids and reversibility at entry
had no effect on CSS.
When individual COPD symptom scores were
examined, a similar pattern was observed with
significant (Po0:05) differences for breathlessness,
chest tightness, cough, and sleep disturbance for
both formoterol groups compared with placebo
(Fig. 2). Improvements in individual symptom
scores were not statistically significantly different
between the formoterol groups.
The mean use of as-needed medication de-
creased progressively during treatment in both
formoterol groups (Fig. 3). The total daily number
of inhalations taken (Table 2; Fig. 3) and the night-
time usage were significantly (both Po0:05) lower
for the formoterol groups compared with placebo.
Day time reliever usage was significantly reduced
vs. placebo in the FORM bid+prn group (0.35 [95%M
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Figure 2 Mean reduction in symptom scores during the 6-
month treatment period. Po0:05, Po0:01,
Po0:001 vs. placebo. FORM bid+prn, formoterol bis
in die (twice-daily)+pro re nata (as-needed); FORM bid,
formoterol bis in die (twice-daily).CI: 0.66, 0.05]; Po0:05) but not in the FORM bid
group (0.22 [95% CI: 0.53,0.08]; P ¼ 0:15). The
percentage of reliever medication-free days (no
day or night-time usage) was significantly (Po0:05)
higher in both the FORM bid (5.50% [95% CI: 0.21,
10.78%]) and FORM bid+prn (8.23% [95% CI: 3.01,
13.46%]) groups compared with placebo. There
were no significant differences in reliever usage on
any variable between the formoterol groups.Severe exacerbations
In total, 92 patients experienced at least one
severe exacerbation of COPD during the study
(FORM bid+prn: n ¼ 23; FORM bid: n ¼ 35; placebo:
n ¼ 34). There was no difference between the
FORM bid and placebo groups (HR: 1.02 [95% CI:
0.63, 1.63]; P ¼ 0:95). The relative risks of severe
exacerbation were numerically lower in the FORM
bid+prn group compared with the placebo group
(HR: 0.62 [95% CI: 0.37, 1.06]; P ¼ 0:079) and the
FORM bid group (HR: 0.61 [95% CI: 0.36, 1.04];
P ¼ 0:068).Health-related quality of life
Large improvements were noted in HRQL through-
out the 6-month study period in each treatment
group, including the placebo group (Fig. 4 and
Table 2). No treatment differences were apparent
between the FORM bid and placebo groups at visits
3 or 5. Significant treatment differences were seen
at visit 5 in SGRQ Symptoms domain scores: FORM
bid+prn vs. placebo (5.47 [95% CI: 8.86, 2.08];
ARTICLE IN PRESS
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Figure 4 Changes in health-related quality of life score during the 6-month treatment period. Po0:01 vs. placebo
and vs. FORM bid. FORM bid, formoterol bis in die (twice-daily); FORM bid+prn ¼ formoterol bis in die (twice-daily)+pro
re nata (as-needed).
Maintenance and as-needed formoterol in COPD 1517P ¼ 0:002) and FORM bid+prn vs. FORM bid (4.63
[95% CI: 8.02, 1.25]; P ¼ 0:007).Efficacy on treatment withdrawal
Within 3 weeks of withdrawal of formoterol, FEV1
and slow VC recordings approached baseline values
in both formoterol groups. These decreases in FEV1
and slow VC were significant in both the FORM bid
group (Po0:001 and Po0:01, respectively) and the
FORM bid+prn group (both Po0:001) relative to
placebo (Table 3). Furthermore, compared with the
placebo group, withdrawal of formoterol resulted
in a significant (Po0:001) decline in PEF in both
formoterol groups (Table 3). The loss of improve-
ment in PEF in the FORM bid+prn group was greater
than in the FORM bid group (Po0:05; Table 3).
Withdrawal of treatment led to an increase in CSS
and some deterioration in aspects of HRQL in each
formoterol group. Compared with the placebo
group, the deterioration in the symptom domain
of the SGRQ was significant on withdrawal of
treatment in the FORM bid group (increase 3.68
[95% CI: 0.94, 6.43]; P ¼ 0:0086) and in the FORM
bid+prn group (increase 4.74 [95% CI: 2.00, 7.48];
Po0:001). There was no evidence of rebound
deterioration in lung function or symptoms vs.
baseline values in either formoterol group.Tolerability
The frequency of AEs throughout the study was low
(FORM bid 3.8 events, FORM bid+prn 3.0 events,
placebo 4.5 events) per 1000 treatment days. The
only AEs with an incidence in X3% of patients inany group were respiratory infections and phar-
yngitis. Undesirable class effects of b2-agonists
(palpitations, cramps, tremor) were reported in
o1% of patients in all groups. Abnormal cardiovas-
cular events, including ECG abnormalities, were
also reported with a similar incidence in all groups.
There was a similar incidence of serious AEs
(SAEs) in each of the treatment groups (FORM bid:
n ¼ 13, FORM bid+prn: n ¼ 7, placebo: n ¼ 9). This
included three deaths in male patients (68–75 years
old), two in the FORM bid group and one in the
FORM bid+prn group, but were considered unre-
lated to study treatment. SAEs were mainly related
to the patients’ underlying disease. Thirty-one
patients discontinued due to AEs during the treat-
ment period: (FORM bid+prn: n ¼ 8, FORM bid:
n ¼ 13, placebo: n ¼ 10). One patient in the FORM
bid group discontinued due to an AE during follow-
up. No safety concerns arose from laboratory
measurements, vital signs, or ECG. The number of
laboratory abnormalities/changes emerging during
the treatment period was similar in all groups.Discussion
This 6-month study demonstrates the benefits of
regular treatment with formoterol 9 mg bid via
Turbuhalers in the management of COPD. Further-
more, these benefits were seen independent of
patients’ initial response to a single dose of b2-
agonist. Additional doses of formoterol were also
shown to be as effective as terbutaline for as-
needed symptom relief. Consistent and significant
improvements were seen in both formoterol groups
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M. Campbell et al.1518for all lung function parameters (FEV1, morning
PEF, and slow VC) and all COPD symptom scores
(breathlessness, chest tightness, cough, and sleep
disturbances) measured. These effects on lung
function, symptom scores and reliever use were
maintained throughout the study period in both
formoterol groups, with no clinical signs of
decreasing bronchodilator effects indicative of
tachyphylaxis.
There was a larger improvement in FEV1 with
formoterol 4.5 mg as needed compared with
terbutaline 0.5mg as needed in addition to
maintenance formoterol treatment, though this
increase in efficacy with as-needed formoterol
was not observed for the other primary variable
(CSS). This indicates that some patients benefit
more from using formoterol as needed than
terbutaline as needed, on top of regular formo-
terol treatment 9 mg bid. This may be as a result
of formoterol’s longer duration of bronchodilation
compared with that of terbutaline.
In mild-to-moderate persistent asthma, the
benefits of maintenance or as-needed formoterol
include a reduction in severe exacerbations.15–17
The efficacy of formoterol in the treatment of
acute asthma and COPD exacerbations has also
been demonstrated.18–20 However, in the present
study, maintenance formoterol with terbutaline
as reliever had no effect on the prevention of
COPD exacerbations. The trend for a reduction in
the relative risk of COPD exacerbations with
formoterol as both maintenance and as-needed
therapy compared with formoterol maintenance
treatment alone, could be a chance finding, but
may warrant further investigation.
Another surprising result was the clinically
significant (44 unit decrease)8 improvement in
total SGRQ score that occurred in the placebo arm
in this study. In two previous studies, formoterol
12 mg metered dose bid via Aerolizers, and 9 mg
bid via Turbuhalers, both enhanced patients’
health status over 3–12 months with no improve-
ments seen with placebo6,21; indicating that
detection of any improvement in patients’ well-
being with formoterol was possibly impaired in
this study due to a marked placebo response
during the initial 6 months of treatment.
A novel aspect of this study design was the
inclusion of a 3-week, single-blind, washout
period, in which all patients received placebo
bid plus terbutaline as-needed. Most of the
improvements in efficacy measures obtained
during the treatment period were lost after
cessation of formoterol treatment, although no
rebound increases in symptoms or deteriorations
in lung function or health status were observed
ARTICLE IN PRESS
Maintenance and as-needed formoterol in COPD 1519compared with baseline. Notably, following the
washout period, total SGRQ scores worsened in
both formoterol groups, particularly in the symp-
tom domain, upon replacement with placebo plus
terbutaline as needed. Thus, the benefits provided
by formoterol with regard to health status were
apparent within 3 weeks of treatment withdrawal,
but not during the initial 6-month treatment phase.
The largest improvements in FEV1 were seen with
maintenance plus as-needed formoterol treatment,
particularly in patients who showed lower vs.
higher reversibility to a single dose of terbutaline
or formoterol at study entry. This supports previous
assertions (reviewed by Mahler)2 that a single
reversibility test is not predictive of long-term
outcomes with b2-agonists in patients with COPD;
indicating that long-term treatment with formoter-
ol may be equally effective in patients with low or
high reversibility. Indeed, Muir et al.22 conclude
that formoterol is effective in patients with COPD
irrespective of their response to reversibility
testing.
Formoterol was well tolerated when used for
maintenance therapy together with either formo-
terol or terbutaline as needed. No safety concerns
with formoterol were identified within the study, as
measured by AEs, SAEs, discontinuations due to
AEs, and number of COPD exacerbations. AEs were
generally mild and as would be expected from the
population of patients studied. There were very
few b2-agonist class-related AEs, and none of these
were serious. High doses of formoterol are well
tolerated in asthma and COPD patients.23–25 A
recent study in patients with COPD25 showed that
salbutamol and formoterol were equally effective
and well tolerated when given acutely as 10
cumulative doses; extra-pulmonary side effects of
high doses of both inhaled formoterol (total dose
90 mg) and salbutamol (total dose 2mg) were low
and without obvious clinical significance.
Cardiovascular AEs are of most concern for the
safe use of b2-agonists in COPD. Although this
study specifically excluded patients with severe
cardiovascular disease, it did not identify any
clinically important changes in ECG variables, vital
signs, or any other cardiovascular issues during the
study. Incidences of cardiovascular abnormalities
were as expected for the population studied, and
there were no differences between treatments.
The favorable cardiovascular tolerability demon-
strated in both formoterol groups in this
study is supported by results from a 1-year study
of the use of formoterol in COPD, in which ECG
and cardiovascular events were examined during
administration of formoterol (24 mg bid; metered
dose).21An obvious benefit of using formoterol both for
as-needed and maintenance use may be improved
convenience for patients, by reducing the number
of inhalers required for effective bronchodilator
therapy. Multiple inhalers can introduce unneces-
sary complexity, which is undesirable because of
the adverse effect this can have on patient
adherence.26 In the present study, a single inhaler
for both maintenance and relief was not an option,
because of the need to double-blind both main-
tenance and reliever therapy, although this simpli-
fied treatment approach warrants further
investigation in a long-term effectiveness study.
In conclusion, the present study demonstrates
that formoterol 9 mg bid via Turbuhalers is an
effective and well-tolerated maintenance treat-
ment for patients with COPD, providing sustained
improvements in lung function and COPD symptoms
over 6 months. These benefits were seen irrespec-
tive of patients’ initial response to a single test
dose of b2-agonist. The use of as-needed formoter-
ol, as an alternative to as-needed terbutaline on
top of maintenance formoterol treatment, was also
well tolerated and provided some additional
improvements in lung function.Acknowledgements
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